Global Restless Legs Syndrome Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Restless Legs Syndrome treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including Axim Biotechnologies Inc, Bioprojet SCR, Hisamitsu Pharmaceutical Co Inc, Luitpold Pharmaceuticals Inc, Merz Pharma GmbH and others.
A Significant contribution to the Restless Legs Syndrome pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Restless Legs Syndrome pipeline included 10 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Restless Legs Syndrome condition and increased access to investments is encouraging growth of Restless Legs Syndrome drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Restless Legs Syndrome drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Restless Legs Syndrome therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Restless Legs Syndrome pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Restless Legs Syndrome. Further, orphan drug status, fast track designation, grants awarded and other special status for Restless Legs Syndrome pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Restless Legs Syndrome pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Restless Legs Syndrome Pipeline candidates-
A Significant contribution to the Restless Legs Syndrome pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Restless Legs Syndrome pipeline included 10 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Restless Legs Syndrome condition and increased access to investments is encouraging growth of Restless Legs Syndrome drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Restless Legs Syndrome drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Restless Legs Syndrome therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Restless Legs Syndrome pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Restless Legs Syndrome. Further, orphan drug status, fast track designation, grants awarded and other special status for Restless Legs Syndrome pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Restless Legs Syndrome pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Restless Legs Syndrome Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Restless Legs Syndrome drugs
- Late phase: Phase 3 and in-approval Restless Legs Syndrome drugs
- Company overview
- Snapshot
- Restless Legs Syndrome therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Restless Legs Syndrome- Disease Overview
2.2 Restless Legs Syndrome- Pipeline Snapshot
2.3 Restless Legs Syndrome- Pipeline Drugs by Phase
2.4 Restless Legs Syndrome- Pipeline Drugs by Company
2.5 Restless Legs Syndrome- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Axim Biotechnologies Inc Restless Legs Syndrome Drug Pipeline, H2- 2019
3.2 Bioprojet SCR Restless Legs Syndrome Drug Pipeline, H2- 2019
3.3 Hisamitsu Pharmaceutical Co Inc Restless Legs Syndrome Drug Pipeline, H2- 2019
3.4 Luitpold Pharmaceuticals Inc Restless Legs Syndrome Drug Pipeline, H2- 2019
3.5 Merz Pharma GmbH Restless Legs Syndrome Drug Pipeline, H2- 2019
3.6 NLS Pharma Group Restless Legs Syndrome Drug Pipeline, H2- 2019
3.7 Omeros Corp Restless Legs Syndrome Drug Pipeline, H2- 2019
3.8 Seelos Therapeutics Inc Restless Legs Syndrome Drug Pipeline, H2- 2019
3.9 Serina Therapeutics Inc Restless Legs Syndrome Drug Pipeline, H2- 2019
3.10 Vifor Pharma Ltd Restless Legs Syndrome Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Restless Legs Syndrome- Phase 1 Drug Details
4.2 Restless Legs Syndrome- Phase 1 Drug Overview
4.3 Restless Legs Syndrome- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Restless Legs Syndrome- Phase 2 Drug Details
5.2 Restless Legs Syndrome- Phase 2 Drug Overview
5.3 Restless Legs Syndrome- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Restless Legs Syndrome- Phase 3 Drug Details
6.2 Restless Legs Syndrome- Phase 3 Drug Overview
6.3 Restless Legs Syndrome- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Restless Legs Syndrome- Pre-clinical Phase Drug Details
7.2 Restless Legs Syndrome- Pre-clinical Phase Drug Overview
7.3 Restless Legs Syndrome- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Restless Legs Syndrome- Disease Overview
2.2 Restless Legs Syndrome- Pipeline Snapshot
2.3 Restless Legs Syndrome- Pipeline Drugs by Phase
2.4 Restless Legs Syndrome- Pipeline Drugs by Company
2.5 Restless Legs Syndrome- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Axim Biotechnologies Inc Restless Legs Syndrome Drug Pipeline, H2- 2019
3.2 Bioprojet SCR Restless Legs Syndrome Drug Pipeline, H2- 2019
3.3 Hisamitsu Pharmaceutical Co Inc Restless Legs Syndrome Drug Pipeline, H2- 2019
3.4 Luitpold Pharmaceuticals Inc Restless Legs Syndrome Drug Pipeline, H2- 2019
3.5 Merz Pharma GmbH Restless Legs Syndrome Drug Pipeline, H2- 2019
3.6 NLS Pharma Group Restless Legs Syndrome Drug Pipeline, H2- 2019
3.7 Omeros Corp Restless Legs Syndrome Drug Pipeline, H2- 2019
3.8 Seelos Therapeutics Inc Restless Legs Syndrome Drug Pipeline, H2- 2019
3.9 Serina Therapeutics Inc Restless Legs Syndrome Drug Pipeline, H2- 2019
3.10 Vifor Pharma Ltd Restless Legs Syndrome Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Restless Legs Syndrome- Phase 1 Drug Details
4.2 Restless Legs Syndrome- Phase 1 Drug Overview
4.3 Restless Legs Syndrome- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Restless Legs Syndrome- Phase 2 Drug Details
5.2 Restless Legs Syndrome- Phase 2 Drug Overview
5.3 Restless Legs Syndrome- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Restless Legs Syndrome- Phase 3 Drug Details
6.2 Restless Legs Syndrome- Phase 3 Drug Overview
6.3 Restless Legs Syndrome- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Restless Legs Syndrome- Pre-clinical Phase Drug Details
7.2 Restless Legs Syndrome- Pre-clinical Phase Drug Overview
7.3 Restless Legs Syndrome- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
